Search Orphan Drug Designations and Approvals
-
| Generic Name: | pegcetacoplan | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Empaveli | ||||||||||||||||
| Date Designated: | 12/19/2018 | ||||||||||||||||
| Orphan Designation: | Treatment of C3 glomerulopathy | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. 100 5th Avenue, 3rd Floor Waltham, Massachusetts 02451 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | pegcetacoplan |
|---|---|---|
| Trade Name: | Empaveli | |
| Marketing Approval Date: | 07/28/2025 | |
| Approved Labeled Indication: | treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria | |
| Exclusivity End Date: | 07/28/2032 | |
| Exclusivity Protected Indication* : | treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria | |
| 2 | Generic Name: | pegcetacoplan |
|---|---|---|
| Trade Name: | Empaveli | |
| Marketing Approval Date: | 08/20/2026 | |
| Approved Labeled Indication: | treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of kidney function | |
| Exclusivity End Date: | TBD | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







